Study of Diagnostic Performance of [18F]CTT1057 in BCR
Status:
Recruiting
Trial end date:
2023-06-09
Target enrollment:
Participant gender:
Summary
The current study aims at evaluating the diagnostic performance of [18F]CTT1057 as a PET
imaging agent for detection and localization of PSMA positivity in patients diagnosed of
biochemical recurrence of prostate cancer (PCa), using a composite truth standard.
Approximately 190 participants will be enrolled to ensure at least 152 participants to
complete the [18F]CTT1057 PET/CT scan procedure (i.e. investigational imaging agent
administration and successful completion of the PET/CT scan), which will be required for the
calculation of the co-primary endpoints.